The results of the Phase III EMBER-3 trial of imlunestrant, a next-generation oral selective oestrogen receptor degrader (SERD) for patients with hormone receptor-positive breast cancer in ER-positive, HER2-negative advanced breast cancer (ABC), were presented at the SABCS. The study shows that patients with an ESR1 mutation in particular benefit.
Autoren
- Birke Dikken
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
You May Also Like
- From symptom to diagnosis
Abdominal pain – Hernias
- "Survey of Health, Ageing and Retirement in Europe" (SHARE)
Analysis of polypharmacy in ≥65-year-olds
- New perspectives for clinics and research
Ageing, cellular senescence and Parkinson’s disease
- From early intervention to individualization
The new guidelines at a glance
- Artificial intelligence
Dr. ChatGPT: Large language models in everyday clinical practice
- COPD therapy
Drug therapy – Update 2025
- Focus on prevention
Colorectal cancer screening – an update
- From symptom to diagnosis